Protect Pharmaceuticals Appoints Dipak Chattaraj to Board of Directors

Sep 21, 2011, 08:00 ET from Protect Pharmaceuticals Corporation

PRINCETON, N.J., Sept. 21, 2011 /PRNewswire/ -- Protect Pharmaceutical Corporation (the "Company") (OTCBB: PRTT) announced today that Dipak Chattaraj, has been appointed to the Company's Board of Directors.

Mr. Chattaraj was the Chairman of Ranbaxy USA, a global generic pharmaceutical company. With over 35 years of experience, Mr. Chattaraj played a key role in Ranbaxy's global expansion. Mr. Chattaraj recently retired from Ranbaxy as President of Corporate Development, having successfully developed Ranbaxy in the U.S. markets. He has a Masters in Economics and started his career with the State of Trading Corporation of India.  

"Dipak Chattaraj brings invaluable experience and leadership to our board of directors," said Ram Sesha, Chairman and CEO of Protect Pharmaceuticals. "His success in developing and launching pharmaceutical products in the United States should support Protect's future developmental and commercialization activities for its drug delivery product candidates."

About Protect Pharmaceuticals Corporation
Based in Princeton, New Jersey, Protect (PRTT) is a publicly held drug delivery and new product development company. Protect applies its proprietary drug delivery technologies to develop clinically effective drugs and is building a robust pipeline of product candidates based on its proprietary technologies, scientific knowledge and clinical expertise. For more information, visit

Safe Harbor Statement
This news release may contain certain forward-looking statements and information concerning Protect's business, operations, financial condition and prospects. These statements are subject to various risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors. The information set forth herein should be read in light of such risks and uncertainties. The Company assumes no duty or obligation to update these statements at any future date.

SOURCE Protect Pharmaceuticals Corporation